TP-13

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TP-13
TP-13.png
Systematic (IUPAC) name
7-Cyclobutyl-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-phenyl-1,2,4-triazolo[4,3-b] pyridazine
Clinical data
Legal status
?
Identifiers
ATC code ?
Chemical data
Formula C19H19N7O 
Mol. mass 361.400 g/mol
 YesY (what is this?)  (verify)

TP-13 is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It is a subtype-selective partial agonist at GABAA receptors, binding selectively to GABAA receptor complexes bearing α2 and α3 subunits.[1] It has modest anticonvulsant activity although less than that of diazepam,[2] and its main effect is likely to be selective anxiolytic action, as seen with other related α2/3-preferring agonists such as L-838,417.


References[edit]

  1. ^ McCabe C, Shaw D, Atack JR, Street LJ, Wafford KA, Dawson GR, Reynolds DS, Leslie JC. Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour. Neuropharmacology. 2004 Feb;46(2):171-8. PMID 14680756
  2. ^ Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, Garrett EM, Newman RJ, O'Meara GF, Whiting PJ, Rosahl TW, Dawson GR, Reynolds DS, Atack JR. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. Journal of Psychopharmacology. 2007 Jun;21(4):384-91. PMID 17092983